Results 31 to 40 of about 41,587 (192)
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. [PDF]
PLoS ONE, 2014 OBJECTIVE: Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of
Yuka Keyamura +9 more
doaj +1 more source
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice
Translational Oncology, 2017 Atorvastatin is widely used to lower blood cholesterol and to reduce risk of cardiovascular disease–associated complications. Epidemiological investigations and preclinical studies suggest that statins such as atorvastatin have antitumor activity for ...
Ming Hong Shen +5 more
doaj +1 more source
Thermodynamic and Thermomicroscopy Study of Atorvastatin Calcium-Succinic Acid Binary Mixtures
Indonesian Journal of Chemistry, 2017 Binary mixtures of pharmaceuticals significantly affect the physical and chemical properties of each component. The aim of this work was to explore the thermal behavior and solid state transformation of binary mixture of atorvastatin calcium and succinic
Yudi Wicaksono +3 more
doaj +1 more source
Mediators of Inflammation, 2021 Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitor and inhibits cholesterol synthesis. Recently, atorvastatin also showed anti-inflammatory effect in acute lung injury, ameliorating pulmonary gas-blood ...
Lan Wu +4 more
doaj +1 more source
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
Pharmaceuticals, 2022 The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids.
Jae Hoon Kim +10 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2019 The drug–drug interaction profile of atorvastatin confirms that disposition is determined by cytochrome P450 (CYP) 3A4 and organic anion transporting polypeptides (OATPs).
Bridget L. Morse +9 more
doaj +1 more source
Journal of Lipid Research, 2006 Statins do not always decrease coronary heart disease mortality, which was speculated based on increased serum plant sterols observed during statin treatment.
Jogchum Plat +4 more
doaj +1 more source
Direct Regioselective para‐Fluorination via I(I)/I(III) Catalysis
Angewandte Chemie International Edition, EarlyView.A direct, para‐selective fluorination by I(I)/I(III) catalysis is disclosed that does not require substrate pre‐functionalization. This strategy leverages the Leonard link inherent to phenylpropanoate and phenylpropanamides to promote a spirocyclization/para‐selective sequence. The C3‐side chain maps onto a range of common drug scaffolds and allows the
Christoph Roblick +5 more
wiley +1 more source
Drugs - Real World OutcomesIntroduction High levels of low-density lipoprotein-cholesterol (LDL) is a major risk factor for cardiovascular diseases. While treatment with atorvastatin is beneficial, the original atorvastatin may be cost prohibitive to some patients.
Panisa Manasirisuk +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source